Alembic
- Market cap
- ₹ 2,221 Cr.
- P/E
- 7x
- P/B
- 0.95x
- 52-week range
- 70.46 – 117.72
- ROE
- 13%
- ROCE
- 6%
- Dividend yield
- 2.7%
- Debt / equity
- 0
- Sector
- Realty
- Industry
- Residential, Commercial Projects
- Listed on
- NSE, BSE
About
Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical Ingredients Business and the Real Estate Business. The Active Pharmaceutical Ingredients Business is engaged in the manufacturing and marketing of fermentation and chemistry-based active pharmaceutical ingredients (API). The Real Estate Business is engaged in the construction of residential and commercial real estate projects and project management and marketing consultancy. The Company provides certain commercial properties on a lease basis to various tenants. The Company is also engaged in research and development activities in Vadodara. It is also engaged in power generation through co-generation.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Residential, Commercial Projects: 174 companies →Alembic against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)7 against a typical 23.3: cheaper than most peers (1st = cheapest).23rd of 173
- Sales growth−2% against a typical +6.6% from a year earlier.82nd of 134
- Profit growth+4.8% against a typical +2.9% from a year earlier.54th of 108
- Share price, 3 months−3.1% against a typical −9.9%.49th of 147
- Size₹ 2,221.4 Cr. market value against a typical ₹ 129.6 Cr. (1st = largest).35th of 163
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA- by ICRA- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| ICRA | [ICRA]AA- | Stable | 31 Aug 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 31 Aug 2026 | Reaffirmed | [ICRA]AA- | — | ICRA | ₹ 50.5 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 19 May 2026 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2026, dividend and other business matters |
| 12 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 10 Nov 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 12 Aug 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters |
| 13 May 2025 | Financial Results/Dividend/Other business matters | To consider and approve the financial results for the period ended March 31, 2025, dividend and other business matters |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32 | 39 | 49 | 51 | 53 | 58 | 60 | 50 | 56 | 74 | 60 | 49 |
| Expenses | 22 | 28 | 25 | 30 | 33 | 32 | 33 | 30 | 33 | 47 | 40 | 33 |
| Operating Profit | 10 | 12 | 24 | 20 | 20 | 26 | 27 | 20 | 23 | 27 | 20 | 15 |
| OPM % | 31% | 30% | 49% | 40% | 37% | 46% | 45% | 39% | 42% | 37% | 34% | 32% |
| Other Income | 48 | 2 | 2 | 2 | 66 | 4 | 3 | 4 | 65 | 2 | 2 | 6 |
| Interest | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 2 | 3 | 1 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 56 | 11 | 24 | 19 | 82 | 27 | 27 | 20 | 85 | 26 | 18 | 17 |
| Tax % | 8% | 9% | 12% | 10% | 6% | 5% | 12% | 10% | 10% | 13% | 48% | 9% |
| Net Profit | 91 | 61 | 72 | 56 | 121 | 65 | 68 | 62 | 128 | 60 | 67 | 65 |
| EPS in Rs | 3.53 | 2.39 | 2.81 | 2.17 | 4.71 | 2.55 | 2.67 | 2.4 | 5 | 2.34 | 2.61 | 2.53 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 6%
- 5 Years
- 27%
- 3 Years
- 24%
- TTM
- 8%
- 10 Years
- 3%
- 5 Years
- −2%
- 3 Years
- 16%
- TTM
- 1%
- 10 Years
- 11%
- 5 Years
- −3%
- 3 Years
- 4%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 11%
- 3 Years
- 13%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Alembic | ₹ 87.50 | ₹ 2,221 Cr. | 7x | 1x | 13% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Chirayu R. Amin
- Executive Chairman of the Board, Chief Executive Officer
- Raj Kumar Baheti
- Director - Finance, Chief Financial Officer
- Manisha Saraf
- Company Secretary and Compliance Officer
- Pranav Chirayu Amin
- Managing Director, Executive Director
- Shaunak Amin
- Managing Director, Executive Director
- Udit Chirayu Amin
- Managing Director, Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.